UnknownPhase 1NCT01011374

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Retina Associates of Cleveland, Inc
Principal Investigator
Lawrence J Singerman, MD
Retina Associates of Cleveland
Intervention
ranibizumab (Lucentis)(drug)
Enrollment
45 enrolled
Eligibility
18 years · All sexes
Timeline
20092013

Study locations (1)

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01011374 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials